US Patent Issued to Children's National Medical Center on Sept. 22 for "Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer" (Maryland, District Of Columbia Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,742,153, issued on Sept. 22, was assigned to Children's National Medical Center (Washington).

"Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer" was invented by Catherine Bollard (Bathesda, Md.), Conrad Russell Cruz (Bathesda, Md.) and Patrick Hanley (Washington).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides isolated cell compositions for the treatment of cancer, including hematological and solid tumors, comprising a selected, fixed ratio of multiple ex vivo activated lymphocytic cell subsets, including specific immune effector cells directed to specific tumor associated antigens ...